Inhibikase Therapeutics Announces Closing Of $10 Million Concurrent Registered Direct Offering And Private Placement Priced At A Premium To Market Under Nasdaq Rules
Inhibikase Therapeutics Inc IKT:
INHIBIKASE THERAPEUTICS ANNOUNCES CLOSING OF $10 MILLION CONCURRENT REGISTERED DIRECT OFFERING AND PRIVATE PLACEMENT PRICED AT A PREMIUM TO MARKET UNDER NASDAQ RULES